

Open Research Online

The Open University's repository of research publications and other research outputs

Unanticipated bleeding with the etonogestrel implant: advice and therapeutic interventions.

Journal Item

How to cite:

Dickson, Jane; Hoggart, Lesley and Newton, Victoria Louise (2014). Unanticipated bleeding with the etonogestrel implant: advice and therapeutic interventions. *Journal of Family Planning and Reproductive Health Care*, 40(3) pp. 158–160.

For guidance on citations see [FAQs](#).

© 2014 British Medical Journal Publishing Group

Version: Accepted Manuscript

Link(s) to article on publisher's website:
<http://dx.doi.org/doi:10.1136/jfprhc-2013-100817>

Copyright and Moral Rights for the articles on this site are retained by the individual authors and/or other copyright owners. For more information on Open Research Online's data [policy](#) on reuse of materials please consult the policies page.

oro.open.ac.uk

Journal of
**FAMILY PLANNING &
REPRODUCTIVE HEALTH CARE**

**Unanticipated, irregular bleeding associated with the
implant and therapeutic interventions**

Journal:	<i>Journal of Family Planning and Reproductive Health Care</i>
Manuscript ID:	jfprhc-2013-100817
Article Type:	Article
Date Submitted by the Author:	28-Oct-2013
Complete List of Authors:	Dickson, Jane; Oxleas NHS Foundation Trust, Contraception and Sexual Health Hoggart, Lesley; The Open University, Newton, Victoria; Greenwich University,
Keywords:	implants, counselling, long-acting progestogens, qualitative research, unscheduled bleeding

SCHOLARONE™
Manuscripts

Unanticipated, irregular bleeding associated with the implant and therapeutic interventions

ABSTRACT

Objectives

To review irregular bleeding as reason for 'premature' contraceptive implant removal and identify recommendations with regard to bleeding management, which may help to improve implant retention.

Methods

A qualitative study was undertaken in which twenty young women who had their implants removed 'prematurely' and nine contraceptive practitioners were interviewed about their experiences of the contraceptive implant.

Results

The most common reason for premature implant removal was intolerance of bleeding patterns despite what was generally felt to be adequate counselling on this side effect. Clinicians appeared to lack a comprehensive strategy to help improve bleeding patterns, beyond reassurance and encouragement to persevere.

Conclusions

It is important to appreciate the true impact of erratic bleeding on young women. A pragmatic, therapeutic approach to manage bleeding problems should be employed as soon as bleeding becomes difficult to tolerate. This includes management with the Combined Oral Contraceptive pill and mefenamic acid.

Key message points

- Young women warned of the possibility of unanticipated bleeding as an implant side effect may still be unprepared for the impact this has.
- Encouragement to tolerate side-effects can push women towards a 'tipping point' when immediate implant removal is requested and there is disengagement with services.
- Bleeding related issues can be managed in clinical practice, thus helping young women to retain this method of contraception, if they wish to do so.

Introduction

The contraceptive implant (Implanon™, Nexplanon™) is widely recognised as a reliable and cost-effective form of contraception [1], [2]. Continuation rates, however, are of concern. In small scale studies in the UK, Smith and Reuter [3] report continuation rates (within one year) for the implant of

1
2
3 between 67% and 78%; whilst Lakha and Glasier [4] report 75%. Blumenthal et al [5] reports an
4 overall discontinuation rate of 32.7% (within five years) based on an analysis of 11 international
5 clinical trials. It has been calculated that 60% to 64% of implant removals are for
6 irregular/unpredictable bleeding [4], [6], [7].
7

8
9 This paper draws on the findings of a recent research project, commissioned by the London Sexual
10 Health Programme (on young women and implant removal), in order to make suggestions for the
11 management of unanticipated, irregular bleeding associated with the contraceptive implant. The
12 research project sought to identify the reasons why some young women have their contraceptive
13 implant removed within one year of insertion and made several recommendations as to how
14 retention of the implant could be maximised [8]. This article draws on this study in order to make
15 suggestions for bleeding management.
16
17
18
19
20

21 **Methods**

22
23 The project was a qualitative study in which twenty young women (aged 16-22) were interviewed.
24 Most had had their implants removed within a year of insertion, and all of them within three years.
25 Their contraceptive choices were examined, using semi-structured qualitative interviews. The
26 women were identified with the help of practitioners at the sexual health clinics in four London
27 health authorities. Participants were purposively selected to meet the age and 'early' implant
28 removal criteria. Nine Contraceptive and Sexual Health Service clinicians were interviewed also using
29 a semi-structured format. The clinicians taking part in the study may or may not have counselled the
30 young women we interviewed in the study. No attempt was made to match the two sets of
31 participants. The data was analysed using thematic analysis [9] by means of NVivo Software.
32
33
34
35

36 **Results**

37
38 Unsurprisingly, the most common reason given for 'premature' removal was intolerance of bleeding
39 patterns. In some cases, this was the length and irregularity of bleeding and in other cases it was the
40 lack of a regular menstrual period that caused concern. In line with previous research[10], the
41 interviewed clinicians also identified bleeding irregularity as the most common problem but there
42 was inconsistency within the clinician group about how this could be managed.
43
44

45 The contraceptive consultation

46
47 Guidelines for standard practice in implant provision emphasises the importance of adequate
48 counselling about side effects, especially bleeding irregularities, before implant insertion [11]. In the
49 research project, almost universally, the clinicians interviewed believed they provided adequate
50 counselling before insertion. They also noted that irregular bleeding patterns were felt to be the
51 main side effect of the implant and this was therefore the issue most extensively discussed in
52 counselling prior to fitting. They felt it was very important that the bleeding pattern of the implant
53 was communicated and understood by the young woman at the time of the consultation.
54
55

56
57 An underlying belief in the efficacy of extensive counselling led some clinicians to blame inadequate
58 counselling for requests for what was viewed as 'premature' removal.
59
60

1
2
3 *To put it in and take it out and what we find is when their people have had poor counselling,*
4 *they come in and they want it out straight away so you may have a person whose had an*
5 *implant in for about six weeks and she had it put in on her period, her period has continued*
6 *and so coming up to the six weeks she getting anxious, she's getting worried: 'why is this*
7 *taking so long?'. (District 3, Interview 2)*
8
9

10 Most clinicians mentioned that they gave the patient a 'leaflet' at the time of counselling (Usually
11 the FPA Contraceptive implant leaflet [12]). The results from our study, however, indicate that the
12 messages from this leaflet are not being absorbed; and also that women who may have trouble
13 reading the leaflet may not mention this at the initial consultation.
14

15
16 Our analysis of the full data set revealed four issues of note derived from contraceptive counselling.
17

- 18 1. There were significant variations in the standard of pre-insertion counselling.
- 19
20 2. There was a mismatch between the young women's recollection of their contraceptive
21 counselling and the counselling described by the clinicians interviewed. This indicates a
22 discrepancy between what the clinicians thought they were communicating, and what the
23 young women themselves took away from the exchange. Although the clinicians taking part
24 in the study may not have been the same ones who had counselled the young women in the
25 study, this difference is worth noting. It is possible that clinicians are over-confident about
26 the efficacy of their counselling on the possibility of bleeding irregularities.
27
28 3. Even if the young women did recall having been counselled about the possibility of
29 problematic bleeding, they were unprepared for the consequences of this on their personal
30 lives.
31
32 4. They hoped that the bleeding would not happen to them.
33
34
35
36
37

38 *'She gave me a leaflet, I'm dyslexic so I need someone to talk to me in person and be honest with*
39 *me'.(Jo,20)*
40

41 *They didn't say anything about bleeding. I didn't get told nothing about that. (Stacy, 19)*
42

43 *I thought it won't happen to me. I thought it would be only for a little bit, I didn't think it would be*
44 *for four months, you know it's quite a while for bleeding. I just underestimated what she was saying*
45 *basically, because I will admit she did tell me, she did but I just thought it won't happen to me. (Aysa,*
46 *17)*
47
48
49
50
51

52 The reality of bleeding for young women

53

54 The young women had understood the bleeding they experienced whilst using the implant in terms
55 of their 'period', and had not anticipated their bleeding patterns becoming worse. Although many
56 had tolerated bleeding patterns that they found distressing for varying periods of time, those
57 seeking 'premature' removal had eventually found the unpredictability and length of bleeding
58
59
60

1
2
3 patterns unbearable. Bleeding was experienced as exhausting, bad for sexual relationships and
4 expensive in terms of the need to buy sanitary protection. Of particular concern was the constant
5 worry about the potential embarrassment of not knowing when they may start bleeding.
6

7
8 Women who did not experience any bleeding could also be unhappy. The perception that regular
9 menstrual bleeding represents normality can be important and women can be anxious about their
10 fertility when they are not experiencing a regular period. Additionally some of the young women
11 interviewed believed that the bleeding was the cause of other problems such as fatigue, anaemia
12 and weight gain.
13

14
15 *I have to obviously decide what clothes to wear and you have to be very cautious because I can't be*
16 *on the bus with a wet patch, that's embarrassing. (Grace, 19)*

17
18 *I can't handle the periods , it was constant, constant just.... And you'd have a two day break and then*
19 *it would come back on for two months and then you'd have a like a week break and then it would*
20 *come back on for a month and it was just a joke. (Janey, 18)*
21

22
23 *I don't think it's very healthy not to have a period...I don't want the situation...when I'm older they*
24 *say it's going to be hard for me to have kids because I had the implant .(Aysa,17)*

25
26 *I just constantly bled for three months straight.... I was constantly tired, the doctors diagnosed*
27 *anaemia so I got to the point that it was time to take it out. (Ella, 22)*
28

29
30 *The period makes you eat more and I'm trying to lose weight at the moment.(Stacy, 19)*
31
32
33
34

35 Many of the clinicians interviewed for this study also expressed frustration with the unpredictable
36 nature of implant bleeding:
37

38
39 *We would counsel to say wait four to six months but the truth is there is actually no proper*
40 *definition of how long the unpredictable bleeding pattern is going to continue, we just don't*
41 *know. We just don't know. (District 2, Interview 2)*
42

43
44 *The big let-down, which is a real let-down, is the problem with the bleeding because we*
45 *can't..... because it's so unpredictable and so varied and there is no way....I can't predict who*
46 *is going to get what (District2, Interview2)*

47
48 However, most clinicians also expressed a sense of disappointment when asked to remove an
49 implant 'prematurely' and specified time periods, for example six months to a year, when they
50 would attempt to persuade the patient to retain the implant. However, as we have shown elsewhere
51 [8] this sort of approach could contribute towards young women reaching a 'tipping point' – this is
52 the point at which nothing short of removal is acceptable. Resistance to removal can also lead to loss
53 of respect for the clinician and the feeling that bodily autonomy has been overridden.
54

55
56 Reaching the 'tipping point'
57
58
59
60

1
2
3 The study found that the request for 'premature' implant removal was usually multi-factorial. Often
4 several factors contributed – not only an accumulation of side effects but also external factors such
5 as change in relationship and a sense of lost autonomy. Although another factor may have proved to
6 be the final impetus for removal, it was clear from the data that bleeding irregularity, was either the
7 major, or the only, underlying cause of dissatisfaction pushing young women towards their
8 individual 'tipping point'. When this happened there was nothing further that could be done to help
9 alleviate the symptoms because they were despondent having been encouraged to tolerate side-
10 effects too long, rather than to return to the clinic as soon as they were concerned.

11
12
13
14 There was some evidence that interventions were attempted, but that these may have been too
15 late. Some young women had experienced an attempt at controlling bleeding and this may not have
16 worked for them, or they had not been able to comprehend the rationale of taking something
17 additional when the obvious cause could be removed.

18
19
20 *I thought that would be too much taking the pill as well...the pill makes you put on weight as*
21 *well and I just didn't feel good about taking it. (Stacy,1 9)*

22
23 Additionally, although several of the clinicians interviewed acknowledged that there were methods
24 of managing bleeding, they did not appear to be aware of a rationale as to what therapeutic
25 intervention could be used and when. As mentioned above, there also appeared to be frustration
26 amongst the clinicians about the unpredictability of the bleeding, rather than any confidence about
27 the possibility of pro-actively helping with this side-effect.

28
29
30 *The majority of the reasons why people want it removed is because of irregular bleeding and*
31 *they may have bled now for six weeks, they're really fed up so then trying to convince*
32 *somebody, 'keep it in and I'll give you something on top of it and it'll settle'... sometimes it's*
33 *very difficult to maybe convince them to go down that route. (District1, Interview 3)*

34
35
36 One of the clinicians acknowledged that a key to helping women continue with the method could be
37 to advise them - at the time of pre-insertion counselling - about how any future bleeding problems
38 could be managed.

39
40
41 *Whereas...you give them good guidance, tell them they can have something to control the*
42 *bleeding and sometimes that can actually almost stop the bleeding, not always but it can do*
43 *and sort of revert the system back to, to sort of being a non-period type method, that they*
44 *will, they will be happy to continue it. (District3, Interview 2)*

51 52 Discussion

53
54 It is important to remember that the young women's recollections of their counselling may differ
55 from the recollections of clinicians. Our interviews with practitioners indicate that these clinicians
56 believe they are counselling adequately, and are likely to assume that requests for 'premature'
57
58
59
60

1
2
3 removal are due to inadequate counselling. This may be the case for some women, but our study has
4 shown that even in cases where young women have been made aware of the possibility of irregular
5 bleeding, the clinician's messages are not always being fully absorbed. The young women each have
6 their own interpretations of the advice they have been given, and individualised responses to their
7 experiences of side effects. It was apparent from our study that the predominant reason for request
8 for implant removal was irregular bleeding. It was also evident that:
9

- 10
11 1. Young women had not been prepared for the reality of prolonged bleeding or irregular
12 bleeding patterns even when they could recall being informed at their initial consultation.
- 13 2. They often persevered, waiting for the bleeding pattern 'to settle', so often tolerated
14 significant amount of discomfort and inconvenience.
- 15 3. Some described bleeding in conjunction with other side effects as being problematic.
16
17

18 It was also apparent that the clinicians were often frustrated and did not have a systematic approach
19 to what could be done to help to improve the situation. Patients were frequently just advised to
20 'persevere' with the symptoms in the hope that these may ultimately resolve – however, when the
21 situation did not resolve, the 'therapeutic window' for some form of intervention had been missed
22 and the women had reached a 'tipping point' at which intervention was no longer possible. Also, it is
23 important to recognise the real impact of troublesome bleeding – the impact it has on sex-life,
24 relationships and finances, and the anxiety caused by unpredictability. It would therefore seem
25 important to intervene as soon as possible when bleeding is presented as a problem, rather than
26 encouraging acceptance of the situation.
27
28

29
30 Research into methods of controlling the problematic bleeding related to the contraceptive implant
31 is inconclusive, so a pragmatic approach to the management of bleeding problems should be
32 employed [13].
33

34
35 During the normal menstrual cycle, estrogen is responsible for the early development of endometrial
36 glands and spiral arterioles and for proliferation of the uterine stroma. Progestogen is responsible
37 for the dilatation and thinning of the spiral arterioles. Continuous low dose progestogen (released by
38 the implant) predisposes to breakthrough bleeding because the vessels proliferate and become
39 disordered with a 'leaky' basement membrane, there is decreased glandular and stromal support,
40 and reduced epithelial integrity [14]. High dose progestogen leads to pseudo-decidualisation and
41 endometrial stability.
42
43

44 Prostaglandins are also important in the mechanism which controls uterine bleeding. Inflammatory
45 prostaglandins, produced by conversion of arachidonic acid by cyclo-oxygenase 2, recruit white cells
46 and sensitise pain receptors. White cell influx is also important in breakthrough bleeding, so
47 reducing this process by provision of non-steroidal anti-inflammatory agents e.g. mefenamic acid,
48 has a potential effective role.
49
50

51 Guidance for the control of unscheduled bleeding related to hormonal contraception [15]
52 recommends that other possible causes for bleeding are initially excluded, e.g. exclusion of sexually
53 transmitted infection, pregnancy and other genital tract pathology. Once the clinician is confident
54 that the cause of the bleeding is implant-related a number of options are available.
55
56
57
58
59
60

- 1
2
3 1. The best approach is to provide estrogen, usually in the form of the combined oral
4 contraceptive pill. This can be given either cyclically or continuously, initially for three
5 months. If symptoms resolve, but then deteriorate when treatment is stopped, it can be
6 given for the entire duration of implant use if necessary. A preparation such as Microgynon™
7 is ideal, as this is a relatively progestogenic preparation. The estrogen will lead to stromal
8 proliferation which helps to support the bleeding vessels and the relative high dose of
9 progestogen will promote pseudo-decidual change. There is no reason that this regime
10 cannot be commenced as soon as abnormal bleeding becomes problematic. There is
11 evidence to support the use of estrogen in the management of bleeding with other
12 progestogenic methods [16], and it is this evidence which was extrapolated to provide the
13 FSRH Guidance.
- 14
15
16
17 2. In cases where estrogen use is contraindicated e.g. focal migraine, there has sometimes
18 been a tendency to use a desogestrel progestogen only pill (e.g. Cerazette™) to try to
19 alleviate bleeding. However, particularly in the early stages of implant use, this can confound
20 the problem further by contributing to the 'low dose progestogen' instability. In this
21 situation, a better intervention would be to use a non-steroidal anti-inflammatory drug such
22 as mefenamic acid. There is no indication to use an anti-fibrinolytic agent e.g. tranexamic
23 acid, as the mechanism of these drugs is to impair plasmin activation. This action is not
24 important in the management of troublesome implant bleeding, unless there is associated
25 menorrhagia. Cerazette™ may have a role in helping bleeding where implant bleeding has
26 been stable but subsequently becomes troublesome e.g. after one or two years of use.
- 27
28
29 3. There has been research to study the effect of the antibiotic doxycycline on the troublesome
30 bleeding caused by the implant. It had been proposed that as a powerful matrix
31 metalloproteinase inhibitor (an enzyme responsible for endometrial breakdown and
32 remodelling) it may be beneficial. However, one randomised controlled trial [17] concluded
33 that the benefits of use are not significant. Nevertheless, this does not mean that it may not
34 have a beneficial effect if there is co-existent infection with Chlamydia or Mycoplasma
35 genitalium, which may be contributing to endometrial instability.
- 36
37
38 4. Finally, there is a role for high dose progestogens when short term arrest of bleeding is
39 required e.g. norethisterone 5mg tds.
- 40
41
42

43 Conclusions

44
45 In order to maximise compliance with the contraceptive implant, clinicians need to demonstrate an
46 empathetic and pro-active approach to the management of bleeding problems. From the time that
47 contraceptive counselling is first undertaken; bleeding patterns should be discussed with patients,
48 including advice about an 'open door approach' to the management of bleeding problems. It needs
49 to be acknowledged that as soon as the bleeding pattern is distressing to the patient, it is a problem.
50 There are no guarantees that perseverance with the implant without intervention will ensure
51 improvement or acceptance. In fact, if this advice is given and there is no resolution, the patient may
52 lose faith in their medical professional.
53
54
55
56
57
58
59
60

1
2
3 If there is no contraindication, the combined oral contraceptive pill is the most effective
4 intervention. If there are contraindications, mefenamic acid e.g. 500mg tds for 1 week can be given.
5 Other management options can be tried on a pragmatic but non-evidence based approach.
6

7 References

- 8
9
10 1. National Institute for Health and Clinical Excellence (NICE) CG30 Long-acting reversible
11 contraception: the effective and appropriate use of long-acting reversible contraception. London:
12 NICE, 2005. <http://guidance.nice.org.uk/CG30> [Accessed 21/10/2013]
13
14 2. Mavranезouli I. The cost effectiveness of long-acting reversible contraceptive methods in the UK:
15 analysis based on the decision-analytic model developed for the National Institute for Health and
16 Clinical Excellence (NICE) clinical practice guideline. *Human Reproduction* 2008;23(6):1338–1345.
17
18 3. Smith A, Reuter S. An assessment of the use of Implanon in three community services. *Journal of*
19 *Family Planning and Reproductive Health Care* 2002;28(4):193–96.
20
21 4. Lakha F, Glasier AF. Continuation rates of Implanon in the UK: data from an observational study in
22 a clinical setting. *Contraception* 2006;74:287–289.
23
24 5. Blumenthal PD, Gemzell-Danielsson K, Marintcheva-Petrova M. Tolerability and clinical safety of
25 Implanon. *European Journal of Contraception and Reproductive Health Care* 2008;13(Suppl. 1):29–36.
26
27 6. Harel Z, Biro FM, Kollar LM, Rauh JL. Adolescents' Reasons for and Experience after
28 Discontinuation of the Long-Acting Contraceptives Depo-Provera and Norplant. *Journal of*
29 *Adolescent Health* 1996;19:118–123.
30
31 7. Rai K, Gupta S, Cotter S. Experience with Implanon in a north east London family planning clinic.
32 *The European Journal of Contraception and Reproductive Health Care* 2004;9:39–46.
33
34 8. Hoggart L, Newton VL, Dickson J. Understanding LARC adherence: an in-depth investigation into
35 sub-dermal contraceptive implant removal amongst teenagers in London. A report for the London
36 Sexual Health Commissioning Programme. 2013.
37
38 9. Braun V, Clarke V. Using thematic analysis in psychology. *Qualitative Research in Psychology*
39 2006;3:77–101.
40
41 10. Mansour D, Korver T, Marintcheva-Petrova M, Fraser IS. The effects of Implanon on menstrual
42 bleeding patterns. *Eur J Contracept Reprod Health Care* 2008; 13:13-28
43
44 11. Faculty of Sexual and Reproductive Healthcare Clinical Effectiveness Unit (April 2008)
45 Progestogen-only Implants
46
47 <http://www.fsrh.org/pdfs/CEUGuidanceProgestogenOnlyImplantsApril08.pdf> [accessed
48 21/10/2013].
49
50 12. FPA (November 2012) Your guide to the contraceptive implant
51 <http://www.fpa.org.uk/sites/default/files/contraceptive-implant-your-guide.pdf> [accessed
52 21/10/2013].
53
54
55
56
57
58
59
60

1
2
3 13. Mansour D , Bahamondes L, Critchley H et al. The management of unacceptable bleeding
4 patterns in etonorgestrel-releasing contraceptive implant users. *Contraception* 2011;83:202-210.
5

6 14. Livingstone M, Fraser IS. Mechanisms of abnormal uterine bleeding. *Hum Reprod Update*
7 2002;8:60-67.
8

9 15. Faculty of Sexual and Reproductive Healthcare Clinical Effectiveness Unit (May 2009)
10 Management of Unscheduled Bleeding in Women Using Hormonal Contraception
11

12 <http://www.fsrh.org/pdfs/UnscheduledBleedingMay09.pdf> [accessed 21/10/13].
13

14 16. Abdel-Aleem H, d'Arcangues C, Vogelsong K, Gulmezoglu AM. Treatment of vaginal bleeding
15 irregularities induced by progestin only contraceptives. *Cochrane Database Syst Rev* 2007; 4:
16 CD003449.
17

18 17. Weisberg E, Hickey M, Palmer D et al. A randomised controlled trial of treatment options for
19 troublesome uterine bleeding in Implanon users. *Human Reproduction* 2009 24(8): 1852-1861.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60